Preparing for FDA QSIT Inspections: What to Expect

QSIT inspection readiness is a source of real stress for pharma and medical device quality teams. The stakes are high and the process starts fast. The moment an FDA investigator walks through the door, credentials are presented, Form FDA 482 (Notice of Inspection) is issued, an opening meeting begins, and a base of operations is set up inside your facility. Every step demands clarity, coordination, and compliance.

The issue most teams run into isn't a lack of quality. It's a lack of practice demonstrating that quality under pressure. A clear, rehearsed approach is what keeps your team confident, your systems transparent, and your facility ready at any time.

What Is an FDA QSIT Inspection?

Since January 1, 2000, QSIT has served as the primary inspection framework used by FDA investigators to evaluate medical device manufacturers globally. An FDA QSIT (Quality System Inspection Technique) inspection is a standardized approach the U.S. Food and Drug Administration uses to evaluate the quality systems of regulated manufacturers.

This includes companies involved in pharmaceuticals, medical devices, biologics, food, and cosmetics. The QSIT methodology focuses on assessing whether a company's quality system is established correctly, maintained effectively, and meets regulatory standards.

The QSIT framework is outlined in Compliance Program (CP) 7382.845, Inspection of Medical Device Manufacturers, which provides guidance to FDA field and center staff for conducting inspections and enforcing key regulatory requirements. These include:

• The Quality System Regulation (21 CFR Part 820)
• Medical Device Reporting (21 CFR Part 803)
• Medical Device Tracking (21 CFR Part 821)
• Corrections and Removals (21 CFR Part 806)
• Registration and Listing (21 CFR Part 807)

Key Characteristics of the QSIT Method

• Subsystem-Oriented: Inspections focus on four major quality system subsystems as Management Controls, CAPA, Design Controls, and Production & Process Controls.
• Top-Down Logic: Investigators start by reviewing management-level systems and then drill down into procedures, records, and implementation.
• Sampling-Based: The FDA uses data sampling to evaluate records and identify trends or compliance risks without inspecting every file.
• Flexible and Risk-Based: QSIT allows FDA to scale the depth of an inspection based on past compliance history and the potential impact on public health.

The QSIT method is not only used to detect noncompliance but also to evaluate whether a company's quality system is strong, preventive, and aligned with regulatory expectations.

4 Major Subsystems of QSIT

Rather than performing a random or unfocused inspection, QSIT allows FDA investigators to concentrate on four critical subsystems:

1. Management Controls: This subsystem evaluates how senior leadership ensures that the quality system is effectively established and maintained. It includes oversight of internal audits, management reviews, and the delegation of responsibility for compliance-related activities.
2. Corrective and Preventive Actions (CAPA): CAPA focuses on how well a company identifies, investigates, and resolves quality issues to prevent recurrence. Investigators will assess the effectiveness and documentation of your problem-solving processes and your ability to implement lasting fixes.
3. Design Controls: For companies involved in product development, this subsystem reviews how design processes are planned, verified, validated, and documented. It ensures that products meet user needs, intended uses, and FDA safety and effectiveness standards.
4. Production and Process Controls: This area examines how consistently and reliably your manufacturing processes produce quality products. It includes equipment calibration, environmental monitoring, in-process controls, and compliance with written procedures.

The QSIT inspection framework is designed to identify systemic issues that could compromise product quality or safety. Investigators employ a top-down approach, beginning with management's oversight of the quality system and progressing to documentation, implementation, and operational controls to assess a company's adherence to compliance standards.

Top-Down Inspection Approach

The FDA's QSIT inspection process follows a top-down methodology, which means investigators begin by evaluating your company's overarching systems and policies before examining specific documents and records. Here's how this structured approach unfolds:

• Starts at the Management Level: Investigators begin by assessing Management Controls, such as how your leadership ensures compliance with FDA regulations, allocates resources, and oversees quality-related decision-making.
• Focuses on System Effectiveness: The emphasis is not only on whether systems exist but also on how effectively they are implemented. Investigators will want to see that your systems are working in practice, not just on paper.
• Reviews High-Level Quality Policies and Procedures: Policies such as your Quality Manual, SOPs (Standard Operating Procedures), and internal audit reports are reviewed to ensure they align with FDA expectations and reflect actual practices.
• Drills Down into Operational Records: Once high-level controls are reviewed, investigators move deeper into the organization by examining supporting documentation, such as batch records, training logs, CAPA reports, and equipment maintenance logs.
• Follows the Flow of Decision-Making: Investigators trace how decisions made by senior management influence day-to-day quality operations. This can involve reviewing how a risk identified during an internal audit led to a CAPA and how that CAPA was implemented on the production floor.
• Evaluate Compliance Consistency: The goal is to ensure that your entire quality system functions cohesively, from top-level strategy down to line-level execution.
• Identifies Systemic Weaknesses: By starting at the top, investigators can more easily spot patterns, gaps, or inconsistencies that might indicate systemic noncompliance across multiple departments or processes.
• Enables Efficient Risk-Based Assessment: The top-down approach allows the FDA to focus its inspection resources on the areas of greatest potential risk, ensuring a more efficient and targeted evaluation.

This structured approach emphasizes control, visibility, and accountability at all levels of your quality system. Preparing your management team and ensuring alignment between policy and practice is essential for a successful QSIT inspection.

Atlas

See what the FDA knows about your next investigator.

30 minutes with the founder. No pitch deck.

See it live

Key Focus Areas During a QSIT Inspection

The FDA's QSIT inspection follows a structured approach, focusing on critical components of your quality system. Investigators assess whether your documentation, implementation, and processes align with regulatory requirements and demonstrate a culture of compliance. Below are the core areas they will examine.

1. Document and Procedure Review First

One of the first steps in an FDA QSIT inspection is a thorough review of your documentation. Investigators will evaluate everything from SOPs to quality manuals to verify that your systems are clearly defined and compliant. These documents must be up-to-date, accessible, and fully aligned with FDA regulations.

• Investigators review Standard Operating Procedures (SOPs), quality manuals, and record-keeping systems.
• Documentation must reflect actual practices and regulatory expectations.
• Gaps, outdated documents, or inconsistencies can raise red flags.

2. Evaluation of Implementation and Compliance

Once documentation is reviewed, investigators assess whether procedures are being followed in practice. This phase reveals if your team is truly executing what's outlined in your policies and if your systems are delivering consistent compliance outcomes.

• Investigators observe how procedures are implemented on the floor.
• Internal audit reports and training records are commonly reviewed.
• Evidence of near-real-time quality monitoring and issue resolution is key.

3. Sampling and Record Analysis

FDA investigators will often verify compliance by sampling product lots and analyzing related records. This ensures that your products meet safety and quality requirements and that your documentation supports each decision made during production.

• Investigators sample product batches and related testing data.
• Batch records, test results, and deviations are thoroughly reviewed.
• Discrepancies between records and product quality can indicate systemic issues.

4. Interviews and Personnel Interaction

Interviews are a critical part of the QSIT process. Investigators speak with staff to evaluate their understanding of processes, roles, and regulatory responsibilities. Your team must be knowledgeable and confident in representing your quality system.

• Key personnel will be asked to explain SOPs and responsibilities.
• Lack of awareness or inconsistency in answers can impact inspection outcomes.
• Training records are reviewed to confirm competency across roles.

5. Management Controls Scrutiny

Investigators will assess how management oversees and supports the quality system. This includes verifying whether senior leaders are actively involved in quality oversight, resource allocation, and decision-making when deviations occur.

• Management's role in supporting quality is closely reviewed.
• Investigators look for corrective action tracking and resource planning.
• Regular management reviews and follow-ups on CAPAs are expected.

6. Deep Dive Into CAPA System

The CAPA (Corrective and Preventive Action) subsystem is one of the most scrutinized areas in a QSIT inspection. It reflects how your company identifies, resolves, and prevents recurring quality issues, ensuring long-term compliance and safety.

• Investigators check for timely identification of nonconformances.
• CAPA records must show root cause analysis and documented follow-up.
• Preventive actions should demonstrate systemic improvements.

7. Design Control Assessment (If Applicable)

If your company is involved in product design (such as devices or biologics), FDA investigators will review how design inputs, outputs, validations, and changes are managed. This ensures the safety and effectiveness of the final product.

• Design plans, risk analysis, and validation protocols are inspected.
• Design reviews must be documented and traceable.
• Any design changes must follow documented change control procedures.

8. Production and Process Controls Verification

The inspection wraps up with a focus on production and process controls. Investigators verify that equipment, facilities, and personnel are capable of producing consistent, compliant products under controlled conditions.

• Equipment maintenance, calibration, and environmental controls are assessed.
• Batch processing records are checked for compliance with SOPs.
• Any deviations in manufacturing must be investigated and documented.

Conclusion

QSIT inspections are a core part of demonstrating a working quality system. By focusing on the subsystems above, you can prepare thoroughly and reduce the risk of systemic findings. Atlas gives quality teams the complete FDA inspection and enforcement data they need to prepare: 700,000+ FDA inspections since 2010, 30,000+ Form 483s and EIRs, 11,828 warning letters, and 6,000+ investigator reports, all searchable in under a second with an AI copilot that turns dense regulatory language into actionable answers in any language.

Need help staying prepared for your next FDA inspection? Book a demo.

FAQs

1. What is an FDA QSIT inspection?

A QSIT inspection assesses the effectiveness of a company's quality system against FDA regulations. The investigator reviews your documentation, procedures, and implementation to confirm compliance.

2. How can I prepare for a QSIT inspection?

Make sure all four quality subsystems are strong, your documentation matches actual practice, and your management team is trained and fluent in FDA expectations. Run mock inspections on each subsystem.

3. How does Atlas help with FDA inspections?

Atlas gives you 700,000+ FDA inspections since 2010, 30,000+ Form 483s and EIRs, 11,828 warning letters, and 6,000+ investigator reports. Sub-1-second AI-enabled search, an AI copilot, and custom analytics help quality teams see what the FDA is actually citing and prepare against it.

4. Why is a CAPA system important for FDA inspections?

CAPA is how you show the FDA that you identify issues, get to root cause, and prevent recurrence. A well-documented, effective CAPA system is one of the biggest drivers of inspection outcomes.